Mycoplasma genitalium is a member of genital mycoplasmas, which is emerging as an important causative agent of sexually transmitted infections both in males and females. The advent of polymerase chain reaction and other molecular methods have made studies on M. genitalium more feasible, which is otherwise a difficult organism to isolate. Besides Chlamydia trachomatis, M. genitalium is now an important and established cause of non gonococcal urethritis (NGU) in men, more so in persistent and recurrent NGU. Multiple studies have also shown a positive association of M. genitalium with mucopurulent cervicitis and vaginal discharge in females as well. The evidences for M. genitalium pelvic inflammatory diseases and infertility are quite convincing and indicate that this organism has potential to cause ascending infection. Lack of clear association with M. genitalium has been reported for bacterial vaginosis and adverse pregnancy outcomes. Diagnosis of M. genitalium infections is performed exclusively using nucleic acid amplification tests (NAATs), owing to poor or slow growth of bacterium in culture. Although there are no guidelines available regarding treatment, macrolide group of antimicrobials appear to be more effective than tetracyclines. The present review provides an overview of the epidemiology, pathogenesis, clinical presentation and management of sexually transmitted infections due to M. genitalium.
Introduction
According to the WHO there are an estimated 448 million new cases of sexually transmitted infections (STIs) which are acquired worldwide annually 1 . If diagnosed in time, these infections can be treated easily with minimal morbidity as well as decreased economic burden. Mycoplasma genitalium is an emerging cause of STIs and has been implicated in urogenital infections of men and women around the world. More than 25 years after its initial isolation from men with non-gonococcal urethritis (NGU) 2 , M. genitalium is now recognized as an important aetiologic agent of acute and persistent male NGU and is responsible for approximately 20-35 per cent of non-chlamydial NGU cases 3, 4 . The role of this organism in male urogenital disease was a significant advancement in our knowledge of STIs, but its role in the inflammatory reproductive tract diseases of women is still not very clear 5 .
The risk factors for M. genitalium infection are typical as for any STI. Researchers in various study groups of women and men aged 21-23 yr identified behavioural risk factors for M. genitalium infection 6 : higher number of partners, younger age during first intercourse, having a partner with infection symptoms, co-infection with other sexually transmitted pathogens like Chlamydia trachomatis 6 . Manhart et al 7 showed that the prevalence of M. genitalium increased by 10 per cent for every additional sexual partner. Asymptomatic carrier state 7 is also a serious epidemiological problem because of transmission to sexual partners and may be vertical transmission from mother to the newborn. Some investigators have reported infection as common as chlamydial infection and trichomoniasis, and more common than gonorrhoea 8, 9 .
In studies conducted in Denmark, the prevalence of infection was 2.3 and 1.1 per cent in women and men, respectively 9 . Takahashi et al 10 demonstrated the positivity rate of M. genitalium DNA in urine from asymptomatic healthy young Japanese men as 1 per cent; among female students in Japan the prevalence of M. genitalium was 2.8 per cent 6 . Tosh et al showed high prevalence rate of 13.6 per cent in young (14-17 yr of age) sexually active women who tested positive for M. genitalium 11 . Among women and men reporting to an STD clinic in Seattle, M. genitalium was detected in 14 and 9 per cent cases, respectively 12 . Table gives a chronological account of important studies reporting geographic prevalence of M. genitalium.
Taxanomy and general characteristics
Mycoplasma (Latin: fungus form) belongs to class Mollicutes (Latin: soft skin). Despite the lack of a cell wall, many taxonomists have classified Mycoplasma and relatives in the phylum Firmicutes, consisting of low G+C Gram-positive bacteria such as Clostridium, Lactobacillus, and Streptococcus based on 16S rRNA gene analysis. The order Mycoplasmatales contains a single family, Mycoplasmataceae, comprising two genera: Mycoplasma and Ureaplasma. These are amongst the smallest free living microorganisms capable of self-replication. M. genitalium is one out of the so far 15 named mycoplasma species of human origin 13 . In 1981, two mycoplasma strains, G-37 and M-30 were first isolated from two men with nongonococcal urethritis (NGU) 2, 14 . Later in 1983 these were named as M. genitalium, the twelfth mycoplasma species recovered from humans 15 .
The genus Mycoplasma contains very small bacteria, with sizes ranging from 0.2 to 0.7 µm. The shape depends on the particular mycoplasma species which may vary from spherical, filamentous or flask/ pear-like. M. genitalium is a motile flask-shaped mycoplasma with terminal tip-like structure which . These organisms are difficult to culture and it may take from a few weeks to a few months before a culture shows visible growth. The mycoplasmas penetrate the surface of the agar and grow in the underlying medium through deposition of manganese dioxide (MnO 2 ). The colonies appear brown and have a typical "fried egg'' appearance (size: 200-400 µm): a dense, dark, granulated nucleus, bordered by a thin, light zone 2, 17 .
GENOME
In 1995 M. genitalium complete genome sequence was published making it the second bacterium after Haemophilus influenzae to have its genome fully sequenced
18
. It is the species with the smallest genome of all mycoplasmas studied so far with a genome of only 580 kb. Although most mycoplasma genomes have a low guanine plus cytosine (G+C) content, with the range of 24-33 per cent G+C, the M. genitalium genome has a comparatively higher G+C content of 32 per cent 18 . The small genome of M. genitalium made it the organism of choice in 'The Minimal Genome Project', a study to find the smallest set of genetic material necessary to sustain life 19 .
PATHOGENESIS
The pathogenesis of M. pneumoniae has been studied extensively and due to the close genetic resemblance, certain features in the pathogenesis of M. pneumoniae can be applied to M. genitalium. Though M. pneumoniae is primarily found in the respiratory tract, and M. genitalium in the urogenital tract, both organisms have been shown to cross tissue barriers. M. genitalium has been shown to attach to different cell types, including erythrocytes, Vero cells, fallopian tube cells, respiratory cells and spermatozoa 13, 20 .
M. genitalium has several virulence factors that are responsible for its pathogenicity. These include the ability to adhere to host epithelial cells using the terminal tip organelle with its adhesins, intracellular localization, the release of enzymes and the ability to evade the host immune response by antigenic variation. M. genitalium lipid-associated membrane proteins (LAMPs) play an important role in the genito-urinary tract inflammatory reaction 20 . Although mycoplasmas are shown to produce hydrogen peroxide and superoxide metabolites, much of the tissue damage is related to the host cell responses. The stimulation and suppression of cells (including lymphocytes, monocytes, macrophages) through induction of cytokine production (mainly TNF-α, IL-1α, IL-1β, IL-6, IL-8 and IL-10) have significant role in pathogenesis. Some of the mycoplasmal cell components can also act as superantigens (i) Adhesion to host epithelium -For any Mollicute to colonize and cause infection, adhesion is the first prerequisite. Mycoplasmas are primarily considered surface parasites of mucous membrane cells as these adhere tenaciously to the epithelial linings of the respiratory or urogenital tract, rarely invading tissues. The urogenital tract appears to be the primary tissue infected by M. genitalium, but the adherence does not appear to be restricted to uroepithelial cells in vitro 13 . Adhesin molecules, clustered at the tip structure of the flask shaped polar cell have been intensely studied both in M. genitalium and M. pneumoniae 21 13 . Whether the same occurs in vivo has not been proven. However, from clinical experience with patients receiving multiple courses of highly active antibiotic treatment with temporary improvement but subsequent relapse, it seems likely that such mechanisms may act in at least in a subset of patients 13 .
(iii) Antigenic variation -Mycoplasmas, in order to evade host immune response, show antigenic variation of their surface components. Surface lipoproteins of mycoplasmas show antigenic variation and over generations these have evolved to generate higher frequency of phenotypic heterogeneity even in a small population of these organisms. Other mechanisms such as mimicry of host antigens may also assist in their survival within the host cells 33, 34 . There are two basic mechanisms for this. Either the organism controls the expression of the virulence factors molecules in accordance to the environmental changes through a signal transduction pathway or the organism may spontaneously generate mutant phenotypes which survive the changes in their environment i.e. host cell responses 33 . In order to evade the host immune system, proteins P140 and P110 of the MgPa have the capacity to undergo antigenic variation, thus changing the genetic sequence of the MgPa with subsequent production of variants that are not recognised by the host immune system 13, 35 . Other survival mechanisms of this organism may be the ability to mimic host cell antigens and the intracellular location within professional macrophages 13 .
Tissue damage observed in M. pneumoniae infections is due to the host cell response and this may indicate what occurs during in M. genitalium infections. Mycoplasmas interact with many components of the immune system, which may lead to production of cytokines and macrophage activation. Some cell components may also act as super antigens and induce a hightened autoimmune response 36 .
(iv) Enzymes -Alvarez et al 37 found that in the glycolytic pathway, the activity of the glycolysis enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) brings about attachment of M. genitalium to human vaginal and cervical mucin in female. Thus GAPDH acts as a ligand to receptors mucin and fibronectin, particularly in vaginal and cervical disease. M. genitalium translocates its cytoplasmic enzymes to the cell membrane surfaces to enhance host tissue colonization 38 . In addition, methionine sulphoxide reductase (MsrA) can be released to enhance the pathogenicity of its small genome 39 . MsrA is an antioxidant repair enzyme of the bacterium. It restores proteins that have lost their biological activity due to the oxidation of their methionines, thereby protecting the bacterium protein structure from the host oxidative 
INFECTIONS IN HUMANS
(A) Urogenital infection in men -Urethritis, which is a common sexually transmitted disease (STD) in heterosexual men, is classified as gonococcal or nongonococcal depending on the presence or absence of Neisseria gonorrhoeae 3 . In approximately 30 per cent of the patients with NGU, neither a bacterial nor a mycoplasmal agent is recovered on usual laboratory medium but some in whom a pathogenic microorganism cannot be identified, respond to treatment with antimicrobial agents that are active against C. trachomatis or U. urealyticum 40, 41 . These observations imply that other more fastidious mycoplasmas or other microorganisms susceptible to antimicrobial agents, such as tetracycline, macrolides and fluoroquinolones may be involved in NGU 3 . Due to difficulties in culturing M. genitalium, only a few epidemiological studies have been conducted after the discovery of the organism. Since DNA probe 42 and PCR assays 43 were developed for detecting M. genitalium, this mycoplasma has now been detected more often in patients with acute NGU than in those without urethritis 44 . It has been shown to cause urethritis in subhuman primates inoculated intraurethrally 45, 46 . and in 13.2 51 to 15.6 per cent 54 of those at urology clinics. An earlier study from our centre showed that M. genitalium was detected in 6 per cent (6/100) of NGU cases. The infection rate was 7.1 per cent (5 of 70) among the HIV positive individuals whereas only one HIV negative NGU case was found to be positive (3.3%). The association of M. genitalium was independent of the presence of C. trachomatis and U. urealyticum 55 . The prevalence of this mycoplasma in men without urethritis who attended STD clinics is 0.8 to 9.1 per cent 4,44,48.50-52 , whereas that in asymptomatic men who attended urology clinic is 0 to 2 per cent 53,54 . Thus, most studies document that M. genitalium is evident significantly more often in patients with acute NGU than in controls without urethritis. Further, the prevalence of M. genitalium is 18.4 to 45.5 per cent in patients with acute nonchlamydial nongonococcal urethritis (NCNGU) and in most studies the prevalence is significantly higher than that in patients with acute chlamydia positive NGU or without urethritis regardless of whether they were recruited at STD or urology clinics 4, 44, 51, 53, 54 . The prevalence of M. genitalium in men with gonococcal urethritis is likely to be lower than that of C. trachomatis 3 . Most patients with NGU associated with C. trachomatis or U. urealyticum respond to antibiotic therapy. However, when neither organism is detected, NGU sometimes persists or recurs within 6 wk of treatment 56, 57 . Various studies show that M. genitalium may have a significant role in persistent or recurrent NGU 5, 52, 58 . It has been detected in the prostate of about 4 per cent of the patients with chronic abacterial prostatitis 59 but there is currently insufficient evidence to suggest that it could be an important cause of the disease 60 .
(B) Urogenital infections in women -Compared to the number of studies in men, only a few studies on the role of M. genitalium in women have been conducted 5 .
(i) Cervicitis -A few studies have addressed the correlation between M. genitalium infection and cervicitis. One of the major problems in interpreting these studies has been the varying definitions of cervicitis. Some studies have considered the presence of 10 polymorphonuclear lymphocytes (PMNLs)/high power field (hpf) in a cervical smear significant, whereas others considered 30 PMNLs/hpf to define cervicitis 13 . One early study by Uno et al 59 defined cervicitis by endocervical discharge and > 20 PMNL/hpf and detected M. genitalium in 5 of 64 women as compared to none of 80 asymptomatic pregnant women 61 . In a US study using archived cervical secretions from 719 women collected on filter paper, it was found that M. genitalium was strongly associated with cervicitis being detected in 7 per cent of all the women examined but in 11 per cent of women with cervicitis (> 30 PMNLs/ hpf) and in 5 per cent of women without cervicitis 60 . In a multivariate logistic regression analysis correcting for other factors found to be associated with cervicitis, and excluding the 172 women infected with N. gonorrohoeae and/or C. trachomatis, M. genitalium remained strongly associated with cervicitis (OR 3.1; 95% CI 1.5-6.8), further supporting an independent role for M. genitalium as a cause of cervicitis. (iv) Adverse pregnancy outcome and infertilityThere is little information available on the role of M. genitalium in causing adverse pregnancy outcome, either as preterm labour, abortion or stillbirth. In one study M. genitalium was detected in only 4 per cent of mid-trimester vaginal swabs from 124 women delivering preterm 68 . This is probably slightly higher than the prevalence in a normal population of pregnant women as estimated in another study 69 where only 0.7 per cent of women pregnant in the first trimester were M. genitalium positive. Regarding infertility, only indirect evidence has been presented. In a Danish study 70 , serum samples from 308 infertile women were investigated for antibodies to M. genitalium by immunoblotting against whole cell proteins of M. genitalium and M. pneumoniae as well as against a recombinant MgPa antigen. Among the women with tubal factor infertility, 22 per cent were seropositive as compared to 7 per cent of women with either male factor infertility or unexplained infertility with normal tubes.
The results of animal experiments offer substantial evidence for the pathogenicity of M. genitalium for the urogenital tract of subhuman primates and the agent is sexually transmitted between partners 13 . It seems reasonable to conclude, that M. genitalium can cause mucopurulent cervicitis although the demonstration of an antibody response is lacking. M. genitalium is sexually transmissible with transmission rates similar to those of C. trachomatis 13 . The role of M. genitalium in women is less well established than in men, and further studies are needed to address its relation to PID and late sequelae such as infertility. Only indirect evidence exists for infertility, and BV and adverse outcome of pregnancy does not appear to be associated with M. genitalium infection. As in men, randomised controlled clinical trials aiming at determining the optimal treatment of the infection are needed.
Association of M. genitalium with other STDs
As the mode of transmission is common amongst all sexually transmitted infections, co-infection of M. genitalium with other pathogens has been observed by many authors. In a study by Yokoi et 
ANIMAL MODELS
Animal studies are useful to establish the transmissibility of M. genitalium in human. Although there are severe limitations of urogenital studies in animals, till now chimpanzees are considered the best animal models for studying male urethritis caused by M. genitalium 13 . Intraurethral inoculation of M. genitalium in male chimpanzees has been shown to lead to infection in them and the organisms were isolated from blood in some cases 45, 46 . Animal studies of female M. genitalium infections have been more rewarding than those performed in male animals. Lower primates like rhesus and cynomolgus monkeys have decreased susceptibility to infection 13 . Studies performed in men with NGU and their female partners showed that M. genitalium was transmitted sexually as efficiently as C. trachomatis, which has been studied in more details 48, 78, 79 . Based on both the concordance rates among partners and on DNA typing showing the same sequence type among partners, it is beyond doubt that M. genitalium is a sexually transmitted pathogen 80 , but further studies are required to confirm.
DIAGNOSIS
Mycoplasma identification and laboratory diagnosis of mycoplasmal infections has been based on classical bacteriological tests including morphology, cultural characteristics, physiological and serological properties. New tests based on molecular analysis of genomic DNA, ribosomal RNAs, cell proteins and lipids appear to push aside the classical tests and one may expect that the molecular tests will shortly become the prevailing tests in mycoplasma identification 17 .
(i) Sample collection
Specimens appropriate for the detection for M. genitalium by culture or non-cultural methods include urethral swab, urine, endocervical swab and endometrial biopsy. Calcium alginate, Dacron or polyester swabs with aluminium or plastic shafts are preferred. Wooden-shaft cotton swabs should be avoided because of potential inhibitory effect. Swabs should always be removed from specimens before transportation to the laboratory 81 . Specimens should be inoculated at the bedside whenever possible by using appropriate transport and/or culture media. SP4 is considered to be a good transport as well as culture medium for M. genitalium. If immediate transportation to the laboratory is not possible, specimens should be refrigerated, but not beyond 24 h. Mollicutes can be stored for long periods in appropriate growth and transport medium at -80°C or in liquid nitrogen. Storage at -20°C is deleterious to detection, even by non-culture methods. Mycoplasmas of human origin can be undertaken on the laboratory bench and/or in a class 2 safety cabinet 81 .
(ii) Staining and Culture techniques
Direct detection of M. genitalium in the samples with the help of different staining techniques is nearly impossible due to their small size and lack of a cell wall.
However, DNA fluorochromes like Hoechst 33258 or acridine orange stain may be applied to body fluids after centrifugation. M. genitalium grows slowly with the prototype strain G37 producing colonies in 6 wk or more 82 . After initial isolation of two M. genitalium strains in 1981, no subsequent isolate was recovered from the genital tract until 1996, when Jensen et al 83 reported isolation of the organism on agar using tissue culture as an enrichment culture for eventual growth on Friis medium.
Sucrose phosphate based culture medium (SP4) played a major role in the discovery of M. genitalium. This medium designed to isolate mycoplasmas and spiroplasmas was developed by Tully et al 2 at the National Institutes of Health (NIH), Maryland, USA, and consisted of mycoplasma broth base supplemented with glutamine, yeast extract, bovine serum, penicillin and phenol red as the indicator. Evidence of mycoplasmal growth was an increase in turbidity as well as the acidic pH change from red to yellow of the phenol red indicator, due to glucose fermentation by the organism 84 . The layer of cells adhering to the container surface was scraped off to inoculate a solid agar medium (0.6% agarose or 0.8% Noble agar in broth base) before anaerobic incubation at 37˚C. Signs of growth in the medium occurred very slowly; with a colour change only occurring after 50 days.
Another medium is the (Pleuro Pneumonia like Organisms) PPLO broth which has been extensively used for the culture of M. genitalium. It can also be used for transport of urethral swabs. The procedure can be made selective for mycoplasmas by filtering the sample through 0.45 µm syringe filter. The tubes are incubated in 5 per cent CO 2 and observed thrice daily for any colour change till 15 days. As soon as the colour change to red-pink is seen in the absence of any turbidity of the medium, the growth is subcultured to corresponding PPLO agar plates. PPLO agar plates are incubated at 37°C with 5 per cent CO 2 for 15 days. The plates are observed daily under the microscope for any growth till 15 days. Once the colonies appeared, the organism is identified according to standard biochemical methods and staining by Dienes and Giemsa stains as per the standard methods 81 . The shape of the colonies is like other mycoplasmas but not typically 'fried egg'.
Considering the susceptibility of cultured cells to mycoplasma infection with a variety of reported species, and also with the knowledge of propagation of fastidious strains of M. hyorhinis in cell cultures 85 , attempts were made to grow M. genitalium in cell cultures (e.g. Vero cell lines) 83 . This approach proved to be very efficient but extremely time-consuming 13 . As there is no reliable medium for the direct isolation of M. genitalium, detection is carried out by PCR. Nevertheless, culture is important for obtaining organisms for susceptibility testing and is a topic of continuing research.
(iii) Serodiagnosis
The classical recommended tests include growth and metabolic inhibition by specific antiserum, as well as direct and indirect immunofluorescence tests applied to mycoplasma colonies. In some cases more sensitive tests based on principles of ELISA, immunobinding, immunoblotting, immunofluorescence and immunoperoxidase test have been applied to mycoplasma diagnosis. The cross-reactions between M. pneumoniae and M. genitalium have significantly hampered the use of specific serology for diagnosis and epidemiological studies 17 . Till date, no serologic test for genital mycoplasmas have been standardized and made commercially available for diagnostic use.
(iv) DNA probes and PCR
Before the development of PCR methods, a few attempts were made using DNA probes. The design of radiolabelled oligonucleotide probes targeting the 16S rRNA was reported to have a detection limit of approximately 1000 organisms 86 and could be tailored to detect only M. genitalium. Clinical studies using such probes have not been reported, but actually, the sequence information from this study was used in one of the first publications on PCR for M. pneumoniae 87 . Some newer quinolones are highly active. For example, the reported MIC is 0.06 to 0.12 μg/ml for sparfloxacin, 0.06 to 0.12 μg/ml for grepafloxacin, 0.05 μg/ml for gemifloxacin and 0.03 to 0.06 μg/ml for trovafloxacin [103] [104] [105] . However, ofloxacin and ciprofloxacin show only moderate activity at 0.5 to 1 and 2 μg/ml, respectively 101, 102 . Till now no universally accepted standards are established for pH, medium, incubation conditions, or duration of incubation for performing mycoplasmal susceptibility test. No MIC breakpoints specific for these organisms are endorsed by any regulatory agency.
Till date, there are no published guidelines or recommendations for treating M. genitalium positive urethritis. Only a few results of antimicrobial chemotherapy in men with M. genitalium positive urethritis have been reported 44, 50, 52, 58 . In addition, these studies have some limitations, such as a small number of patients and no detection of other potentially important genital mycoplasmas or other types of organisms. Therefore, it is impossible to draw conclusions on the best strategy for managing M. genitalium positive nongonococcal urethritis 3 . As a specific microbiological diagnosis of mycoplasmal infection is seldom made, appropriate treatment provides antimicrobial coverage for the organisms that cause the particular syndrome. Accordingly NGU is treated with doxycycline (100 mg orally twice a day for 7 days) or azithromycin (1.0 gm as a single oral dose) to provide activity against C. . The slow growth M. genitalium, and its ability to invade and multiply in the epithelial cells might account for its persistence in urethra or other sites, specially following treatment 60 . M. genitalium was found in some patients with chronic NGU who had been treated originally with doxycycline (100 mg/day for 10 days), and a 6 wk course of erythromycin (500 mg QDS) 107 . Others are found M. genitalium persisting in some patients with acute NGU after treatment with doxycycline (200 mg followed by 100 mg for 13 days) or erythromycin 108 , or after treatment with tetracycline (500 mg BD for 10 days) 58 or after treatment with levofloxacin (100 mg TDS for 14 days) 58 . In one study an azithromycin regimen comprising 500 mg in a single dose on day 1 followed by 250 mg OD for 4 days provided excellent cure rates 60 . Further studies are needed to determine the most appropriate treatment for M. genitalium positive acute and chronic NGU and other M. genitaliumassociated infections.
Conclusion
M. genitalium is one of the smallest prokaryote capable of replication, lacks a cell wall and has a characteristic pear/flask shape with a terminal tip organelle. M. genitalium has several virulence factors that are responsible for its pathogenicity. The latter includes its ability to adhere to host epithelial cells using the terminal tip organelle with its adhesins, the release of enzymes and the ability to evade the host immune response by antigenic variation. M. genitalium has emerged as an important cause of sexually transmitted infections in recent times and it is now known as established cause of non gonococcal uretheritis (NGU) in men. It is reasonable to conclude that it is strongly associated with mucopurulent cervicitis in women. The evidence for M. genitalium PID and infertility are quite convincing and indicate that this organism has potential to cause ascending infection but more studies are needed to understand the relationship between M. genitalium and reproductive tract disease in women. Further research is required to understand the dynamics of HIV and M. genitalium coinfections. Though there are variety of in-house PCRs which have been developed for diagnosing the M. genitalium infections, there is a need of highly accurate internationally validated and approved commercial NAAT. All the present evidences support the use of azithromycin as first drug of choice for M. genitalium infections. In conclusion, M. genitalium is an important cause of sexually transmitted infections in both men and women and should be treated with azithromycin when required. 
